[23] Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
- 1 January 1996
- book chapter
- Published by Elsevier in Methods in Enzymology
- Vol. 272, 210-218
- https://doi.org/10.1016/s0076-6879(96)72025-6
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Genetic analysis of the S-mephenytoin polymorphism in a chinese population*Clinical Pharmacology & Therapeutics, 1995
- A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotypePharmacogenetics, 1995
- Biochemistry and molecular biology of the human CYP2C subfamilyPharmacogenetics, 1994
- The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.Journal of Biological Chemistry, 1994
- Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in HumansBiochemistry, 1994
- Isolation and Characterization of Human Liver Cytochrome P450 2C19: Correlation between 2C19 and S-Mephenytoin 4′-HydroxylationArchives of Biochemistry and Biophysics, 1993
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989